Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA. Kempf DJ, et al. Among authors: bernstein bm. J Virol. 2001 Aug;75(16):7462-9. doi: 10.1128/JVI.75.16.7462-7469.2001. J Virol. 2001. PMID: 11462018 Free PMC article.
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E. Hsu A, et al. Among authors: bernstein b. Antimicrob Agents Chemother. 2003 Jan;47(1):350-9. doi: 10.1128/AAC.47.1.350-359.2003. Antimicrob Agents Chemother. 2003. PMID: 12499212 Free PMC article. Clinical Trial.
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J, Cohen D, Johnson M, Sloan L, Fredrick L, Naylor C, da Silva B, Bernstein B; M05-730 Study Group. González-García J, et al. Among authors: bernstein b. AIDS Res Hum Retroviruses. 2010 Aug;26(8):841-5. doi: 10.1089/aid.2009.0307. AIDS Res Hum Retroviruses. 2010. PMID: 20672994 Clinical Trial.
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. Gathe J, et al. Among authors: bernstein b. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81. doi: 10.1097/QAI.0b013e31819c2937. J Acquir Immune Defic Syndr. 2009. PMID: 19225400 Clinical Trial.
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
Zajdenverg R, Podsadecki TJ, Badal-Faesen S, Andrade-Villanueva J, Gathe J, Mingrone H, Fredrick LM, Gaultier IA, Woodward WC, Bernstein BM. Zajdenverg R, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):143-51. doi: 10.1097/QAI.0b013e3181cbd21e. J Acquir Immune Defic Syndr. 2010. PMID: 20134330 Clinical Trial.
563 results